Precision BioSciences (NASDAQ:DTIL) Downgraded to Market Perform at BMO Capital Markets

BMO Capital Markets cut shares of Precision BioSciences (NASDAQ:DTIL – Get Rating) to a market perform rating in a report published on Monday, The Fly reports.

Separately, BTIG Research decreased their price target on shares of Precision BioSciences to $6.00 in a research note on Tuesday, November 15th.

Precision BioSciences Trading Up 2.1 %

Shares of DTIL stock opened at $0.93 on Monday. The company has a 50 day moving average of $1.19 and a 200-day moving average of $1.30. The company has a quick ratio of 3.34, a current ratio of 3.34 and a debt-to-equity ratio of 0.37. Precision BioSciences has a 12-month low of $0.90 and a 12-month high of $3.93. The firm has a market cap of $103.45 million, a P/E ratio of -0.66 and a beta of 1.45.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of DTIL. Swiss National Bank grew its stake in Precision BioSciences by 9.5% in the 1st quarter. Swiss National Bank now owns 114,900 shares of the company’s stock valued at $354,000 after buying an additional 10,000 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Precision BioSciences by 22.2% in the 1st quarter. JPMorgan Chase & Co. now owns 906,366 shares of the company’s stock valued at $2,792,000 after purchasing an additional 164,816 shares during the period. Cambridge Investment Research Advisors Inc. bought a new position in Precision BioSciences in the 1st quarter valued at $48,000. HighTower Advisors LLC bought a new position in Precision BioSciences in the 1st quarter valued at $47,000. Finally, BlackRock Inc. boosted its holdings in Precision BioSciences by 4.0% in the 1st quarter. BlackRock Inc. now owns 4,566,690 shares of the company’s stock valued at $14,067,000 after purchasing an additional 175,176 shares during the period. 50.50% of the stock is currently owned by hedge funds and other institutional investors.

Precision BioSciences Company Profile

(Get Rating)

Precision BioSciences, Inc is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases.